Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Bulletin Du Cancer|January 1, 1993
[Hodgkin disease, clinical stages IA-IIB: evaluation of the value of cisplatin. Preliminary results]M Belhani, M I Belkaïd, R Ahmed-Naceur, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 3, 1999
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDSH Hendel, S Caillat-Zucman, H Lebuanec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patientsP Colonna, J P Jais, B Desablens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stagesJ M Andrieu, J P Jais, P Colonna, et al.
Bulletin Du Cancer|April 1, 1997
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program]J M Tourani, C Jaillon-Abraham, V Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trialJ M Tourani, V Lucas, D Mayeur, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progressionH Hendel, N Hénon, H Lebuanec, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative GroupJ M Tourani, C Pfister, J F Berdah, et al.
Annales D'Endocrinologie|April 7, 2004
[Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry]Ph Jaquet, Ch Cortet-Rudelli, G Sassolas, et al.
Pageof 10